The Lipid–Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet Reactivity
Luis Ortega-Paz,Francesco Franchi,Dominick J. Angiolillo
DOI: https://doi.org/10.1055/s-0044-1782161
2024-03-20
Thrombosis and Haemostasis
Abstract:The interaction of circulating lipoproteins with platelets can increase platelet reactivity, promoting platelet activation, aggregation, and thrombus formation.[1] This can explain why patients with hypercholesterolemia, especially those with familial hypercholesterolemia, and increased levels of low-density lipoprotein (LDL-C) have heightened platelet reactivity.[1] However, the mechanism(s) explaining these observations are not completely elucidated. Among the prevailing hypotheses, it has been postulated that the LDL-C and oxidized LDL-C modulate platelet membrane lipid composition and interact directly via multiple platelet receptors (e.g., CD36 and lectin-like oxidized LDL receptor 1), resulting in hyper-reactivity, morphologic changes, and increased aggregation.[1] Statins have been associated with a reduction in platelet reactivity both in the absence and presence of antiplatelet agents, including aspirin and clopidogrel.[1] These effects have been associated with LDL-C level reduction and pleiotropic effects, including modulation of inflammation.[1] The platelet lipidome also appears to be altered in patients with coronary artery disease (CAD) on statin treatment and upregulated lipids, mainly characteristic triglycerides. In contrast, downregulated lipids mostly compromise glycerophospholipids, which may play a role in the pathophysiology of CAD.[2] [3] The discovery of the role of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in LDL-C metabolism and subsequent development of PCSK9 inhibitors has led to marked reduction of LDL-C with a concomitant decrease in cardiovascular events.[4] Whether these effects are related only to LDL-C reduction or off-target properties, such as a reduction in platelet reactivity, has been debated.[5] Preclinical studies have suggested that elevated levels of circulating PCSK9 are associated with increased platelet reactivity and thrombus formation, potentially by binding to platelet CD36 receptors.[6] [7] Moreover, in a nonrandomized study of patients undergoing percutaneous coronary intervention (PCI) treated with potent oral P2Y 12 inhibitors (i.e., ticagrelor or prasugrel), elevated circulating levels of PCSK9 were associated with increased platelet reactivity and thrombotic events.[8] Functionally synergistic interactions between antiplatelets and PCSK9 inhibitor lipid-lowering drugs may reduce the incidence of atherothrombotic vascular events, as recently reviewed by Schrör et al.[9] Indeed, several randomized studies have been designed to assess the effects of PCSK9 inhibitors on coronary plaque morphology and platelet reactivity.[10] [11] [12] [13] [14] [15] In particular, PACMAN-AMI was a double-blind, placebo-controlled, randomized clinical trial that enrolled patients undergoing PCI for acute myocardial infarction (MI). Patients ( n = 300) were randomized to biweekly subcutaneous alirocumab (i.e., antibody-based PCSK9 inhibitor) or placebo, initiated less than 24 hours after PCI, in addition to high-intensity statin therapy. At 52 weeks, adding subcutaneous biweekly alirocumab to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries compared with placebo.[12] In this issue of Thrombosis and Haemostasis , the PACMAN-AMI investigators report the effects of alirocumab on platelet function in patients with acute MI who had undergone successful PCI.[16] This was a prespecified, powered, pharmacodynamic (PD) substudy of the patients enrolled in Bern University Hospital who were on potent P2Y 12 inhibitors. PD assessments were performed at baseline, 24 hours, 4-, and 52-week. The primary endpoint was P2Y 12 reaction units (PRU) at 4 weeks, as assessed by VerifyNow. Secondary endpoints included aspirin reaction units (ARU) assessed by VerifyNow, platelet-derived noncoding ribonucleic acid (RNAs, microRNAs, and YRNAs), high-sensitivity C-reactive protein (hs-CRP), and a comprehensive lipid panel. The study population ( n = 139) was composed mostly of men (84.9%) with a median age of 58 years, presenting mainly with ST-segment elevation MI (51.8%). The prevalence of conventional cardiovascular risk factors was low, and none of the patients had a prior history of MI, PCI, or coronary artery bypass grafting surgery. Only a small fraction of patients were on aspirin (4.3%) or statins (12.9%); none were oral P2Y 12 inhibitors. At baseline, no differences existed in any of the platelet function tests or assessed biomarkers. Post-discharge, all were prescribed statins, with 98.5% on low-dose aspirin (100 mg). At 4 weeks, 90.6% of the patients were on ticagrelor. Compared to placebo, alirocumab was associated with a significant reduction in LDL-C (24.0 ± 16.2 -Abstract Truncated-
peripheral vascular disease,hematology